Öztürk Furkan, Emiroğlu Canan, Aypak Cenk
Department of Family Medicine, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye.
J Eval Clin Pract. 2025 Feb;31(1):e70004. doi: 10.1111/jep.70004.
The positive effects of vaccination status on the course of Long COVID symptoms have not been fully elucidated. Our aim is to determine the most common Long COVID symptoms in patients monitored in the COVID-19 follow-up clinic and to examine whether there is a difference between the recovery rates of those who are vaccinated and those who are not vaccinated.
Between December 1, 2020 and April 30, 2022, prospectively collected data of 916 patients who were admitted to the COVID-19 follow-up outpatient clinic of a tertiary hospital for the first time were evaluated as a retrospective cohort in this study. The frequencies of the ten most common symptoms in the first and last examinations of 478 patients with Long COVID symptoms were determined, and their recovery was compared. Patients were divided into two groups according to their vaccination status. The values showing the recovery rates obtained for these two groups were compared between themselves again.
The average age of the patients in the study group was 54.43 ± 11.71 years, and 255 (53.3%) were male. The median follow-up period was 10 months. 84.7% of patients had received at least one dose of vaccine. Statistically significant results were found for improvement in all ten symptoms in vaccinated patients compared to the never-vaccinated group. There was no statistically significant difference between the CoronaVac, BNT162b2, and heterologous (CoronaVac+ BNT162b2) vaccine groups. Factors affecting recovery for the three most common symptoms (dyspnea, fatigue, forgetfulness) were examined with univariate logistic regression analysis, and only vaccination or non-vaccination was found to be a significant risk factor.
This study showed that receiving vaccination may be effective in improving Long COVID symptoms. Although there were no statistically significant differences between the inactive vaccine CoronaVac, the mRNA vaccine BNT162b2, and the heterologous (CoronaVac+ BNT162b2) vaccine in terms of reducing Long COVID symptoms, higher recovery rates were detected in those who received the mRNA vaccine BNT162b2.
疫苗接种状态对新冠后遗症症状病程的积极影响尚未完全阐明。我们的目的是确定在新冠随访诊所接受监测的患者中最常见的新冠后遗症症状，并检查接种疫苗者和未接种疫苗者的恢复率是否存在差异。
在2020年12月1日至2022年4月30日期间，对首次入住一家三级医院新冠随访门诊的916例患者前瞻性收集的数据在本研究中作为回顾性队列进行评估。确定了478例有新冠后遗症症状患者首次和末次检查中十种最常见症状的出现频率，并比较了它们的恢复情况。患者根据疫苗接种状态分为两组。再次比较这两组获得的显示恢复率的值。
研究组患者的平均年龄为54.43±11.71岁，男性255例（53.3%）。中位随访期为10个月。84.7%的患者至少接种了一剂疫苗。与未接种疫苗组相比，接种疫苗的患者在所有十种症状的改善方面均发现有统计学意义的结果。科兴疫苗、BNT162b2疫苗和异源（科兴疫苗+BNT162b2疫苗）组之间没有统计学意义的差异。通过单因素逻辑回归分析检查了影响三种最常见症状（呼吸困难、疲劳、健忘）恢复的因素，发现只有接种疫苗或未接种疫苗是一个显著的风险因素。
本研究表明，接种疫苗可能对改善新冠后遗症症状有效。尽管灭活疫苗科兴疫苗、mRNA疫苗BNT162b2和异源（科兴疫苗+BNT162b2疫苗）在减轻新冠后遗症症状方面没有统计学意义的差异，但在接种mRNA疫苗BNT162b2的患者中检测到更高的恢复率。
